BACKGROUND: Aleglitazar, a dual PPAR-α/γ agonist, combines the lipid benefits of 
fibrates and the insulin-sensitizing benefits of thiazolidinediones.
OBJECTIVE: To investigate the pharmacokinetic effects of co-administration of 
atorvastatin or rosuvastatin with aleglitazar.
RESEARCH DESIGN AND METHODS: In a two-cohort, open-label, randomised, 
three-period crossover study, 44 healthy subjects received once-daily oral doses 
of aleglitazar 300 μg, statin (atorvastatin 80 mg or rosuvastatin 40 mg) and 
aleglitazar co-administered with each statin for 7 days. Plasma concentrations 
of each drug were measured and pharmacokinetic parameters determined on day 7 in 
each period.
MAIN OUTCOME MEASURES: Peak observed plasma concentration (C(max)) and total 
exposures (AUC(0 - 24)) of aleglitazar, atorvastatin and rosuvastatin.
RESULTS: C(max) and AUC(0 - 24) to aleglitazar were similar, whether 
administered alone or in combination with a statin. Total exposure to either 
statin was unaffected by co-administration with aleglitazar. C(max) treatment 
ratios for both statins exceeded the conventional no-effect boundary (1.25) when 
administered with aleglitazar.
CONCLUSIONS: Co-administration of aleglitazar with a statin does not alter the 
pharmacokinetic profile of either drug.